挪威奥斯陆白塞病发病率和患病率:二十年基于人群的分析
该研究基于挪威奥斯陆1999至2021年医院行政数据库和挪威结缔组织与血管炎登记库(NOSVAR),经病历人工复核并按国际研究组(ISG)标准和国际白塞病标准(ICBD)分类,纳入至少符合其一标准的58例白塞病患者。发病率为每10万人年0.29(95%CI:0.18,0.41),非挪威裔高于挪威裔(0.44 vs 0.22),患病率从1999年每10万人2.36升至2021年7.14,非挪威裔更高(12.68 vs 4.32)。作者认为发病率与患病率上升可能源于人群遗传变化及更敏感的ICBD标准引入,诊断延迟常见且值得关注。
要点
- 奥斯陆白塞病发病率为每10万人年0.29(95%CI:0.18,0.41),非挪威裔高于挪威裔(0.44 vs 0.22)。
- 患病率从1999年每10万人2.36升至2021年7.14,2021年非挪威裔高于挪威裔(12.68 vs 4.32)。
- 中位诊断延迟为5年(四分位距2-12年),作者认为诊断延迟常见且值得关注。
核心结论
- 白塞病在挪威奥斯陆属罕见病,挪威裔中以女性为主,但非挪威裔总体患病率更高。
- 观察到的发病率和患病率上升可能源于人群遗传变化及更敏感的ICBD标准引入。
- 作者认为诊断延迟常见且值得关注。
研究设计与样本
- 研究从奥斯陆医院行政数据库和挪威结缔组织与血管炎登记库(NOSVAR)中按国际疾病分类第10版修订版白塞病编码(M35.2)识别病例。
- 所有识别病例经病历人工复核,并按国际研究组(ISG)标准和国际白塞病标准(ICBD)分类,符合至少一项标准者纳入。
- 共纳入58例患者,其中43例为 incidental(原文用词),52%为女性,57%为非挪威裔。
主要发现
- 症状起病平均年龄24岁,诊断时平均年龄33岁,中位诊断延迟5年(四分位距2-12年)。
- 发病率为每10万人年0.29(95%CI:0.18,0.41),非挪威裔为0.44,挪威裔为0.22。
- 挪威裔中女性发病率高于男性(0.27 vs 0.08)。
- 患病率1999年为每10万人2.36,2021年为7.14;2021年非挪威裔为12.68,挪威裔为4.32。
- 发病率和患病率似呈上升,但按ISG标准重新分类后趋势下调;校正非挪威裔比例后该趋势显著减弱。
关键数值与推荐
- 病例分类采用国际研究组(ISG)标准和国际白塞病标准(ICBD),符合至少一项标准者纳入。
- 发病率为每10万人年0.29(95%CI:0.18,0.41)。
- 患病率1999年为每10万人2.36,2021年为7.14。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To estimate the incidence and prevalence of Behçet's disease (BD) in Oslo, Norway from 1999 to 2021. METHODS: First, we identified BD cases from the Oslo hospital administrative databases and Norwegian connective tissue and vasculitis registry (NOSVAR) using the code for BD (M35.2) of the 10th revised edition of the International Classification of Diseases. Next, all identified cases were manually chart-reviewed and classified by the International Study Group (ISG) criteria and International Criteria for Behçet's Disease (ICBD). Cases meeting at least one of the two criteria were included. RESULTS: In total 58 patients were included, 43 of them incidental; 52% were female and 57% with non-Norwegian ancestry. The mean age at symptom onset was 24 years and at diagnosis 33 years. The median diagnostic delay was 5 (interquartile range 2-12) years. Incidence was 0.29 (95% CI: 0.18, 0.41) per 100 000 person-years, higher in non-Norwegians (0.44 vs 0.22). Among Norwegians, the incidence was higher in females (0.27 vs 0.08). The prevalence was 2.36 per 100 000 inhabitants in 1999 and 7.14 in 2021, higher for non-Norwegians (12.68 vs 4.32 in 2021). Incidence and prevalence appeared to increase, but reclassification by ISG criteria adjusted the trend downward. This trend was significantly reduced when accounting for the proportion of non-Norwegians. CONCLUSION: BD is a rare disease in Oslo, Norway, with female predominance in Norwegian descendants, but higher prevalence overall in non-Norwegians. The observed increases in incidence and prevalence are likely due to changes in population genetics and introduction of the more sensitive ICBD criteria. Diagnostic delays are common, a significant concern, in Behçet's disease.
引用
- Lorentsen JLL, Brunborg C, Aasebø AT, et al. Incidence and prevalence of Behçet's disease in Oslo, Norway: a two-decade population-based analysis. Rheumatology (Oxford). 2025. PMID: 40279276. doi:10.1093/rheumatology/keaf224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。